|
|
Joined: 12/6/2011
Posts: 3326
|
From Alzheimer's Daily News:
(Source: Reuters) - Pfizer research chief Mikael Dolsten said the company's experimental treatment for Alzheimer's disease is the drug industry's "best chance" to delay progression of the memory-robbing illness."This is so far the best chance the industry has for disease modification in Alzheimer's," he said. Dolsten said Pfizer's drug, bapineuzumab, had far more complete and compelling data from already finished mid-stage clinical trials than Eli Lilly's solanezumab.
Both companies plan to release Phase III data in the second half of this year from their respective large trials. The drugs are meant to be the first to slow progression of Alzheimer's.
Go to full story: http://www.reuters.com
|
|
Joined: 1/24/2012
Posts: 69
|
My husband went through this clinical trial from the placebo stage to the open-label part. He does not have the Apoe4 gene nor does he have the mutation of the Presenil1 gene. It did not do him any good and we followed all the protocols. He had 3 infusions of the open-label before I had to admit him to the pysch hospital because of aggression toward me and our son. I know the amount of the drug varied so perhaps it wasnt enough. I do know that the other two people left in the study were also doing worse. So I dont see what Pfizer is so happy about
|
|
Joined: 12/6/2011
Posts: 3326
|
Thank you, lesa, for the information!
|
|
Joined: 12/5/2011
Posts: 795
|
Yes Lesa,
Thanks for sharing.
Peace and Hope,
Lisa
|
|
Joined: 12/15/2011
Posts: 18692
|
This is old news. JAB posted extensively about the results of the clinical trial for bapineuzumab on the old board.
Iris L.
|
|
|
|